Systemic Sclerosis (Scleroderma)

1. Overview

Systemic Sclerosis (SSc), also known as Scleroderma, is a rare, chronic, multisystem autoimmune connective tissue disease characterised by the triad of vasculopathy, immune dysregulation, and progressive fibrosis affecting the skin and internal organs. [1,2] The name derives from the Greek skleros (hard) and derma (skin), reflecting the hallmark feature of skin thickening and hardening.

SSc represents one of the most challenging rheumatological conditions due to its heterogeneous clinical manifestations, variable disease course, and significant organ-threatening complications. Unlike many autoimmune diseases, SSc uniquely combines vascular injury with fibrotic remodeling, leading to irreversible tissue damage. The disease affects approximately 50-300 per million individuals worldwide, with significant variation based on geographic location and ethnicity. [3]

The clinical spectrum ranges from limited skin involvement with relatively indolent progression to rapidly progressive diffuse disease with life-threatening organ complications. Major causes of morbidity and mortality include Interstitial Lung Disease (ILD), Pulmonary Arterial Hypertension (PAH), Scleroderma Renal Crisis (SRC), and cardiac fibrosis. [4,5] Early recognition, risk stratification, and organ-specific monitoring are critical to improving outcomes in this complex disease.

---

2. Classification and Subtypes

Primary Classification

SSc is classified into two major cutaneous subtypes based on the extent of skin involvement, with distinct autoantibody associations, organ manifestation patterns, and prognoses. [6]

CREST Syndrome

CREST syndrome represents a subset of limited cutaneous SSc, characterized by five cardinal features: [7]

• Calcinosis cutis: Calcium deposits in subcutaneous tissue and skin
• Raynaud's phenomenon: Episodic vasospasm of digital arteries
• Esophageal dysmotility: Lower esophageal sphincter dysfunction and impaired peristalsis
• Sclerodactyly: Skin thickening confined to the fingers
• Telangiectasia: Mat-like dilated capillaries on face, hands, mucous membranes

While historically useful, the CREST acronym is less commonly used today as these features can occur across the SSc spectrum, and not all limited disease patients manifest all five components.

Additional Subtypes

Systemic Sclerosis sine Scleroderma: Internal organ manifestations typical of SSc without significant skin involvement. Comprises ~5-10% of cases. [8]

Overlap Syndromes: SSc features coexist with other connective tissue diseases (SLE, polymyositis/dermatomyositis, rheumatoid arthritis). [9]

Localized Scleroderma (Morphea): Confined skin involvement without systemic features or Raynaud's phenomenon. Not considered true SSc. [10]

---

3. Epidemiology

Incidence and Prevalence

• Prevalence: 50-300 cases per million population globally, with significant geographic variation [3]

  • Highest in North America and Australia
  • Lower in Japan and other Asian populations
  • Europe shows intermediate rates

• Incidence: 10-20 new cases per million per year [3]

• Age Distribution: Peak onset 30-55 years; rare in children (less than 5% of cases) [11]

Demographics

Sex: Marked female predominance with female:male ratio of 3-8:1 overall. [3]

• Ratio increases to 10-14:1 during childbearing years (ages 30-50)
• More balanced ratio in older patients and those with occupational exposures

Ethnicity: [12]

• African-American: Higher incidence, younger age at onset, more diffuse disease, worse prognosis
• Hispanic: Intermediate risk
• Caucasian: Lower risk but most common due to population demographics
• Asian: Generally lower incidence but severe when present

Risk Factors

Genetic Susceptibility: [13]

• HLA Associations: HLA-DRB111, HLA-DPB113:01 (ILD risk), HLA-DRB1*04 (anti-Scl-70)
• Non-HLA Genes: IRF5, STAT4, CD247, BANK1 (shared with other autoimmune diseases)
• Family History: Relative risk increases 13-fold in first-degree relatives

Environmental Triggers: [14]

• Occupational Exposures:
  • "Silica dust (mining, sandblasting, stone cutting): 2-5 fold increased risk"
  • Organic solvents (trichloroethylene, benzene, toluene)
  • Vinyl chloride (plastics industry)
  • Epoxy resins
• Infectious Agents: Possible association with CMV, EBV, parvovirus B19 (not definitively proven)
• Medications: Rare cases associated with bleomycin, pentazocine, cocaine (adulterated)

Hormonal Factors: [15]

• Peak incidence in women of childbearing age suggests hormonal influence
• Pregnancy may trigger disease onset or relapse
• Early menopause slightly increased in SSc patients

---

4. Aetiology and Pathophysiology

The pathogenesis of SSc involves a complex interplay of three fundamental processes: vascular injury, immune activation, and fibroblast dysregulation leading to excessive extracellular matrix deposition. [1,16]

Pathogenic Triad

1. Vascular Injury and Vasculopathy

The earliest detectable abnormality in SSc is endothelial cell damage, which triggers a cascade of vascular pathology: [17]

Initiating Injury:

• Unknown trigger causes endothelial cell apoptosis and dysfunction
• Possible triggers: oxidative stress, autoantibodies to endothelial cells, viral infections, ischemia-reperfusion injury

Endothelial Dysfunction:

• Reduced nitric oxide (NO) production and increased endothelin-1 (ET-1)
• ET-1 is a potent vasoconstrictor and pro-fibrotic mediator
• Imbalance favors vasoconstriction and platelet aggregation

Vascular Remodeling:

• Intimal proliferation and medial hypertrophy narrow vessel lumina
• Adventitial fibrosis
• Capillary dropout and loss of vascular density
• Formation of dilated, irregular "scleroderma capillaries" visible on nailfold capillaroscopy

Clinical Manifestations:

• Raynaud's phenomenon: Episodic vasospasm from exaggerated response to cold/stress
• Digital ulcers: Ischemic injury from severe small vessel disease
• Pulmonary arterial hypertension: Pulmonary vascular remodeling and obliteration
• Scleroderma renal crisis: Acute vasospasm and thrombotic microangiopathy in renal arterioles

2. Immune Dysregulation

Both innate and adaptive immune systems are dysregulated in SSc: [18]

Innate Immunity:

• Type I interferon signature (elevated IFN-α and IFN-inducible genes)
• Dendritic cell activation
• Toll-like receptor (TLR) activation

Adaptive Immunity:

• T-cell Activation:

  • Predominance of Th2 cytokines (IL-4, IL-13) promoting fibrosis
  • Th17 cells produce IL-17, contributing to inflammation
  • Regulatory T-cell (Treg) dysfunction impairs immune regulation

• B-cell Activation:

  • Production of disease-specific autoantibodies (ACA, anti-Scl-70, anti-RNA Pol III)
  • B-cells produce pro-fibrotic cytokines (IL-6, TGF-β)
  • Plasma cells infiltrate affected tissues

Autoantibodies: [6]

• Nearly universal (> 95% ANA positive)
• Mutually exclusive patterns in most patients
• Each antibody associates with distinct clinical phenotype:

3. Fibroblast Activation and Fibrosis

The hallmark of SSc is excessive and progressive fibrosis resulting from persistent fibroblast activation: [19]

Fibroblast Transformation:

• Normal fibroblasts transform into myofibroblasts expressing α-smooth muscle actin
• Myofibroblasts exhibit constitutive activation independent of ongoing stimulus
• Resistant to apoptosis, leading to persistent fibrosis

Pro-fibrotic Mediators: [20]

• TGF-β (Transforming Growth Factor-beta): Master regulator
  • Stimulates collagen production
  • Induces myofibroblast differentiation
  • Promotes epithelial-to-mesenchymal transition (EMT)
• CTGF (Connective Tissue Growth Factor): TGF-β-induced mediator
• PDGF (Platelet-Derived Growth Factor): Fibroblast proliferation and migration
• IL-6, IL-13, IL-4: Pro-fibrotic cytokines

Extracellular Matrix Production:

• Excessive deposition of type I and type III collagen
• Fibronectin, tenascin, proteoglycans accumulate
• Imbalance between matrix production and degradation
• Reduced matrix metalloproteinases (MMPs) and increased tissue inhibitors (TIMPs)

Organ Fibrosis:

• Skin: Dermal thickening, loss of appendages (hair, sweat glands), tethering to underlying fascia
• Lungs: Alveolar wall thickening, honeycombing, restrictive physiology
• Heart: Myocardial fibrosis (replacement and interstitial), conduction abnormalities
• GI Tract: Smooth muscle atrophy and replacement with collagen, dysmotility
• Kidneys: Intimal hyperplasia of arcuate and interlobular arteries (onion-skinning)

Exam Detail: ### Molecular Mechanisms in Detail

TGF-β/SMAD Signaling Pathway:

1. TGF-β binds to type II receptor (TβRII)
2. TβRII recruits and phosphorylates type I receptor (TβRI/ALK5)
3. Activated TβRI phosphorylates SMAD2/3
4. pSMAD2/3 binds SMAD4, translocates to nucleus
5. SMAD complex binds DNA promoter regions of pro-fibrotic genes (COL1A1, COL1A2, ACTA2)
6. Transcription of collagen, fibronectin, α-SMA

Non-canonical TGF-β Signaling:

• PI3K/AKT pathway activation
• MAPK/ERK pathway
• RhoA/ROCK pathway (cytoskeletal changes)
• JAK/STAT pathway

Epigenetic Modifications: [21]

• DNA hypomethylation of COL1A2 gene promoter in SSc fibroblasts
• Histone acetylation changes perpetuate activated phenotype
• MicroRNA dysregulation (miR-29 family downregulated; normally suppresses collagen)

Endothelial-to-Mesenchymal Transition (EndMT): [22]

• Endothelial cells lose markers (CD31, VE-cadherin)
• Acquire mesenchymal markers (α-SMA, vimentin, type I collagen)
• Contribute to pool of fibroblasts and myofibroblasts
• Driven by TGF-β, hypoxia, inflammatory cytokines

Organ-Specific Pathology

Skin: [23]

• Early: Edematous phase with inflammatory infiltrate (perivascular T-cells, mast cells)
• Mid: Proliferative phase with increased fibroblasts and collagen deposition
• Late: Sclerotic/atrophic phase with dense collagen bundles, loss of appendages, dermal/fascial tethering

Lungs: [24]

• ILD Pattern: Most commonly nonspecific interstitial pneumonia (NSIP) (> 70%)
  • Temporally uniform fibrosis with alveolar wall thickening
  • Ground-glass opacities on HRCT
  • Better prognosis than usual interstitial pneumonia (UIP)
• PAH: Proliferative vasculopathy of small pulmonary arteries
  • Intimal hyperplasia, medial hypertrophy, adventitial fibrosis
  • Plexiform lesions in severe cases
  • Increased pulmonary vascular resistance → RV failure

Kidneys: [25]

• Scleroderma Renal Crisis: Acute thrombotic microangiopathy
  • Histology: "Onion-skinning" (concentric intimal hyperplasia of arcuate and interlobular arteries)
  • Arteriolar fibrinoid necrosis
  • Glomerular ischemia and collapse
  • "Triggered by: High-dose corticosteroids, RNA Pol III antibodies, rapid skin progression"

Gastrointestinal: [26]

• Atrophy and fibrosis of smooth muscle layers
• Neural plexus damage (autonomic neuropathy)
• Vascular insufficiency
• Results in: Aperistalsis (esophagus), delayed gastric emptying, pseudo-obstruction, bacterial overgrowth

Heart: [27]

• Primary Cardiac Involvement (distinct from PAH-related RV dysfunction):
  • Myocardial fibrosis (patchy replacement and diffuse interstitial)
  • Conduction system fibrosis → arrhythmias (VT, heart block)
  • Coronary microvascular disease → "scleroderma heart disease"
  • Pericardial involvement (effusion, rarely tamponade)

---

5. Clinical Presentation

SSc presents with protean manifestations affecting virtually every organ system. The clinical course is highly variable, ranging from slowly progressive limited disease to rapidly fatal diffuse disease.

Constitutional Symptoms

• Fatigue: Profound and disproportionate to disease activity; present in > 80% [28]
• Weight Loss: Especially in diffuse disease and GI involvement
• Arthralgias/Arthritis: Non-erosive inflammatory arthritis in 20-50%, often early in disease
• Myalgias: Myositis-overlap in 5-10%

Cutaneous Manifestations

Raynaud's Phenomenon

Nearly universal (> 95% of SSc patients); often the presenting symptom. [29]

Features:

• Triphasic Color Change: White (ischemia) → Blue/Purple (deoxygenation) → Red (reperfusion)
• Triggers: Cold exposure, emotional stress, vibration
• Distribution: Fingers most common; also toes, nose, ears
• Duration: Minutes to hours per episode

SSc-specific Raynaud's Features:

• More severe and frequent attacks than primary Raynaud's
• Painful (ischemic pain)
• Digital ulceration and pitting scars
• Abnormal nailfold capillaroscopy
• Positive ANA or SSc-specific antibodies

Complications: [30]

• Digital Ulcers: 30-50% of SSc patients
  • Ischemic ulcers (fingertips) vs. calcinosis-related ulcers
  • Slow healing, high recurrence rate
  • "Risk factors: Male sex, dcSSc, anti-Scl-70, smoking"
• Digital Pitting Scars: Healed ischemic injuries leaving pitted depressions
• Digital Gangrene: Rare (less than 1%); requires urgent vascular assessment
• Critical Digital Ischemia: Acute, severe ischemia requiring prostacyclin therapy

Skin Thickening (Sclerosis)

Sclerodactyly: [31]

• Thickening and tightening of skin on fingers
• Leads to flexion contractures and functional impairment
• "Claw-like" appearance in severe cases
• Prayer sign (inability to flatten palms together)

Diffuse Skin Involvement (dcSSc):

• Proximal extension to forearms, arms, chest, abdomen, thighs
• Shiny, taut, immobile skin
• Loss of skin folds and wrinkles
• Hyperpigmentation or hypopigmentation ("salt-and-pepper")
• Progression typically peaks within 3-5 years, may stabilize or improve

Modified Rodnan Skin Score (mRSS): [32]

• Semi-quantitative assessment of skin thickness
• Examines 17 body areas, each scored 0-3 (0=normal, 3=severe thickening)
• Maximum score 51
• Used to track disease progression and treatment response
• Scores > 20 indicate severe diffuse disease

Facial Changes

• Reduced Oral Aperture (Microstomia): Difficulty with dental care, eating
• Radial Perioral Furrows: Vertical wrinkles around mouth
• Beaked Nose: Thinning of nasal ala
• Tight, Mask-like Facies: Loss of facial expression
• Telangiectasias: Mat-like dilated capillaries on face, hands, lips, tongue

Calcinosis Cutis

• Calcium hydroxyapatite deposits in subcutaneous tissue [33]
• More common in lcSSc and juvenile SSc
• Distribution: Fingers, extensor surfaces, pressure points, sites of trauma
• Complications: Ulceration, infection, extrusion of chalky material
• Associated with long disease duration

Gastrointestinal Manifestations

GI involvement occurs in > 90% of SSc patients, affecting the entire GI tract from mouth to anus. [26,34]

Gastric Antral Vascular Ectasia (GAVE): [35]

• "Watermelon stomach"
• longitudinal red stripes in gastric antrum
• Chronic GI bleeding → iron deficiency anemia
• Diagnosis: Upper endoscopy
• Treatment: Argon plasma coagulation (APC), laser therapy

Small Intestinal Bacterial Overgrowth (SIBO): [36]

• Results from hypomotility and stasis
• Symptoms: Bloating, diarrhea, malabsorption, weight loss
• Diagnosis: Hydrogen/methane breath testing
• Treatment: Rotating antibiotics (rifaximin, metronidazole, ciprofloxacin)

Pulmonary Manifestations

Lung disease is the leading cause of death in SSc, accounting for > 50% of disease-related mortality. [37]

Interstitial Lung Disease (ILD)

Epidemiology: [24,38]

• Prevalence: 40-75% depending on detection method (higher with HRCT screening)
• More common in dcSSc (up to 75%) than lcSSc (35%)
• Risk factors: Anti-Scl-70 antibodies, diffuse cutaneous disease, African ancestry, male sex

Clinical Presentation:

• Symptoms: Exertional dyspnea, dry cough, reduced exercise tolerance
• Signs: Fine inspiratory crackles (bibasal), clubbing (uncommon)
• Course: Variable - can be rapidly progressive, slowly progressive, or stable

Diagnosis:

• HRCT Chest: Gold standard [39]
  • "NSIP pattern (most common, 70%): Ground-glass opacities ± reticular changes, subpleural sparing"
  • "UIP pattern (20-25%): Honeycombing, traction bronchiectasis, peripheral/basal predominance"
  • "Extent of disease: Quantitative scoring (% lung involvement) predicts mortality"
• Pulmonary Function Tests: [40]
  • "Restrictive pattern: Reduced FVC, reduced TLC"
  • "DLCO reduction: Early and sensitive marker; often precedes FVC decline"
  • FVC less than 70% predicted or DLCO less than 70% indicates significant disease
• 6-Minute Walk Test: Functional assessment; reduced distance and oxygen desaturation predict outcomes

Prognostic Factors: [41]

• Poor Prognosis Indicators:
  • Extent of fibrosis on HRCT (> 20% involvement)
  • FVC less than 70% predicted at baseline
  • Decline in FVC > 10% over 12 months (or 5-10% with symptoms/imaging progression)
  • UIP pattern (worse than NSIP)
  • Anti-Scl-70 antibody
  • Older age at onset

Pulmonary Arterial Hypertension (PAH)

Epidemiology: [42]

• Prevalence: 10-15% of SSc patients
• More common in lcSSc (15%) than dcSSc (5-10%)
• Risk factors: Anti-centromere, anti-U3 RNP, late-stage limited disease, isolated DLCO reduction

Pathophysiology:

• Pulmonary vascular remodeling independent of ILD ("isolated PAH")
• Can also occur secondary to ILD ("ILD-associated PH")
• Increased pulmonary vascular resistance → RV pressure overload → RV failure

Clinical Presentation:

• Symptoms: Exertional dyspnea (earliest), fatigue, chest pain (RV ischemia), syncope (severe), orthopnea (RV failure)
• Signs: Loud P2, RV heave, TR murmur, elevated JVP, peripheral edema, hepatomegaly

Screening: [43]

• Annual screening recommended for all SSc patients
• Echocardiography: Estimate RVSP; RVSP > 40 mmHg or unexplained DLCO less than 60% warrants further evaluation
• DLCO: Isolated reduction (DLCO less than 60% with preserved FVC) suggests PAH
• Biomarkers: Elevated BNP/NT-proBNP

Diagnosis:

• Right Heart Catheterization (definitive): [44]
  • Mean PAP ≥20 mmHg (updated 2022 definition; previously ≥25 mmHg)
  • Pulmonary capillary wedge pressure (PCWP) ≤15 mmHg (excludes left heart disease)
  • Pulmonary vascular resistance (PVR) ≥3 Wood units
• Exclude ILD-PH, chronic thromboembolic PH (CTEPH), left heart disease

Prognosis:

• SSc-PAH has worse prognosis than idiopathic PAH
• 3-year survival historically 50-60% (improved with modern therapies)
• Poor prognostic factors: WHO functional class III-IV, low 6MWT distance, high BNP, low cardiac index

Renal Manifestations

Scleroderma Renal Crisis (SRC)

A medical emergency occurring in 5-10% of SSc patients, SRC is characterized by acute-onset malignant hypertension and rapidly progressive acute kidney injury. [45,46]

Epidemiology and Risk Factors:

• Incidence: 5-10% lifetime risk; higher in dcSSc (10-15%) than lcSSc (less than 1%)
• Timing: Usually within first 3-5 years of disease
• Major Risk Factors:
  • Anti-RNA Polymerase III antibodies (relative risk 5-10×)
  • Rapid skin progression (increasing mRSS)
  • Diffuse cutaneous disease
  • "Corticosteroid use: High-dose steroids (> 15 mg/day prednisone) are a major precipitant"
  • New cardiac events (pericardial effusion, CHF)
  • Recent anemia

Pathophysiology:

• Acute vasospasm and thrombotic microangiopathy of renal arterioles
• Activation of renin-angiotensin-aldosterone system (RAAS) → malignant hypertension
• Ischemic injury to kidney → further RAAS activation (vicious cycle)
• Histology: "Onion-skinning" of arterioles, fibrinoid necrosis, glomerular ischemia

Clinical Presentation: [47]

• Hypertension: Sudden-onset severe hypertension (> 150/90 mmHg; often > 180/110 mmHg)
  • Normotensive SRC in 10-20% (worse prognosis; often on ACEi already)
• Acute Kidney Injury: Rapidly rising creatinine (often to > 400 μmol/L within days)
• Microangiopathic Hemolytic Anemia (MAHA): Schistocytes on blood film, elevated LDH, low haptoglobin
• Thrombocytopenia: From consumption
• Hypertensive Complications:
  • Headache, visual disturbances, seizures (hypertensive encephalopathy)
  • Pulmonary edema (flash pulmonary edema)
  • Left ventricular failure
  • Retinal hemorrhages, papilledema

Investigations:

• Blood: ↑ Creatinine, ↑ Urea, ↑ LDH, ↓ Haptoglobin, ↓ Platelets, schistocytes on smear, ↑ Renin
• Urine: Proteinuria (usually less than 1 g/day; not nephrotic), microscopic hematuria
• Renal Biopsy: Rarely needed; shows thrombotic microangiopathy if performed

Differential Diagnosis:

• Thrombotic thrombocytopenic purpura (TTP)
• Hemolytic uremic syndrome (HUS)
• Malignant hypertension (other causes)
• Antiphospholipid syndrome (catastrophic APS)

Management: [48,49]

Immediate Treatment:

1. ACE Inhibitor (FIRST-LINE):
   • Captopril 6.25-12.5 mg PO every 6-8 hours initially
   • Titrate rapidly to max dose (150 mg/day) OR until BP controlled
   • CRITICAL: Continue ACEi even if creatinine rises (renal function may recover months later)
   • If patient cannot tolerate oral: IV enalaprilat
2. Blood Pressure Target: less than 120/80 mmHg (gradual reduction over 72 hours to avoid ischemia)
3. Add Additional Antihypertensives if needed:
   • Calcium channel blockers (amlodipine, nifedipine)
   • Angiotensin receptor blockers (ARB) - if ACEi not tolerated
   • Avoid beta-blockers (may worsen Raynaud's and peripheral perfusion)
4. Renal Replacement Therapy:
   • Dialysis may be required in 50-80% initially
   • Continue ACEi during dialysis
   • Renal function may recover even after 12-18 months; avoid premature transplant listing

Avoid:

• Corticosteroids: Taper if patient is on steroids; high doses precipitate SRC
• Nephrotoxic agents (NSAIDs, contrast)

Prognosis:

• Pre-ACEi era: less than 10% 1-year survival
• Post-ACEi era: 70-80% 1-year survival
• 50% of dialysis-requiring patients recover sufficient function to stop dialysis (may take 6-18 months)
• Normotensive SRC has worse prognosis (delayed diagnosis)

Chronic Kidney Disease

• Less common than SRC
• Slowly progressive CKD from chronic vascular disease
• Monitoring: Annual creatinine and urinalysis

Cardiac Manifestations

Primary cardiac involvement is often subclinical but contributes significantly to mortality (10-15% of SSc deaths). [27,50]

Types of Cardiac Involvement:

Screening:

• Baseline and annual ECG
• Baseline and annual echocardiography (or if symptoms develop)
• Consider: Holter monitoring (if palpitations/syncope), cardiac MRI (if echo abnormal or high-risk features)
• Biomarkers: NT-proBNP, high-sensitivity troponin

"Scleroderma Heart Disease": [51]

• Primary myocardial involvement from fibrosis and microvascular ischemia
• Patchy replacement fibrosis visible on cardiac MRI as late gadolinium enhancement (LGE)
• Associated with arrhythmias and sudden cardiac death
• Worse prognosis; consider ICD in high-risk patients

Musculoskeletal Manifestations

Arthralgia and Arthritis: [52]

• Non-erosive inflammatory arthritis in 20-50%
• Joint contractures from skin thickening (especially fingers)
• "Prayer sign": Inability to flatten palms together
• Tendon friction rubs (25-65% in dcSSc): Palpable/audible crepitus over tendons; associated with poor prognosis

Myopathy:

• Myositis-overlap syndrome (5-10%): Elevated CK, proximal weakness, inflammatory myositis on biopsy
• Myopathy from disuse or steroids (more common than true myositis)

Bone Resorption: [53]

• Acro-osteolysis: Resorption of distal phalanges (visible on X-ray)
• Associated with severe Raynaud's and digital ulcers
• "Penciling" appearance of distal fingers

Neurological Manifestations

Peripheral Nervous System:

• Trigeminal Neuralgia: 4-10% of SSc patients
• Carpal Tunnel Syndrome: From skin/tendon thickening
• Peripheral Neuropathy: Rare; may be from overlap syndromes

Autonomic Dysfunction:

• GI dysmotility
• Cardiac arrhythmias
• Sexual dysfunction (erectile dysfunction in men, vaginal dryness in women)

Central Nervous System:

• CNS involvement is rare in SSc (unlike SLE)
• Possible cerebrovascular events from vasculopathy

Other Organ Involvement

Thyroid: [54]

• Autoimmune thyroid disease (hypothyroidism or hyperthyroidism) in 10-20%
• Higher than general population; screen with TSH

Sicca Syndrome:

• Dry eyes and dry mouth in 20-40%
• Overlap with Sjögren's syndrome

Sexual Dysfunction:

• Erectile dysfunction in men (30-80%) from vascular and autonomic causes
• Vaginal dryness and dyspareunia in women

Malignancy: [55]

• Slightly increased cancer risk (RR 1.5-2)
• Anti-RNA Polymerase III: Associated with concurrent or temporally-related malignancy (especially within 2 years of SSc diagnosis)
• Cancers: Breast, lung, hematologic

---

6. Differential Diagnosis

SSc must be distinguished from other conditions causing skin thickening, Raynaud's phenomenon, or multisystem involvement.

---

7. Investigations

Diagnosis and monitoring of SSc require a multimodal approach combining clinical, serological, imaging, and functional assessments.

Serological Investigations

Autoantibody Testing: [6,56]

• Antinuclear Antibody (ANA):

  • Positive in > 95% of SSc
  • "Patterns: Centromere (ACA), nucleolar (anti-Scl-70, anti-RNA Pol III), speckled (anti-U1 RNP in overlap)"
  • Negative ANA makes SSc unlikely (but SSc sine scleroderma may be ANA-negative)

• SSc-Specific Antibodies (mutually exclusive in most patients):

Inflammatory Markers:

• ESR and CRP: Usually normal or mildly elevated (unlike active SLE or RA)
• Elevated in overlap syndromes or complications (infection, myositis)

Other Laboratory Tests:

• Complete Blood Count: Anemia (chronic disease, GAVE, MAHA in SRC), thrombocytopenia (SRC, overlap with SLE)
• Renal Function: Baseline creatinine; monitor for SRC
• Liver Function Tests: May be abnormal in primary biliary cholangitis overlap
• Creatine Kinase (CK): Elevated in myositis-overlap
• Thyroid Function: Screen for autoimmune thyroid disease
• Urinalysis: Proteinuria, hematuria (renal involvement)

Imaging and Functional Assessments

Pulmonary Assessment

High-Resolution Computed Tomography (HRCT) Chest: [39,57]

• Indications: All SSc patients at baseline; repeat if symptoms or PFT decline
• Findings:
  • "NSIP: Ground-glass opacities, reticular changes, subpleural sparing, lower lobe predominance"
  • "UIP: Honeycombing, peripheral/basal fibrosis, traction bronchiectasis"
• Quantification: Semi-quantitative scoring (extent of disease) predicts mortality

Pulmonary Function Tests (PFTs): [40]

• Baseline and annually (or more frequently if abnormal)
• Spirometry:
  • "FVC: Reduced in ILD (restrictive pattern)"
  • "FEV1/FVC ratio: Preserved or increased (restrictive, not obstructive)"
• Lung Volumes: TLC reduced in ILD
• Diffusion Capacity (DLCO):
  • Most sensitive marker for lung involvement
  • Isolated DLCO reduction (less than 60% with normal FVC) suggests PAH
  • DLCO reduced in both ILD and PAH
• 6-Minute Walk Test: Functional assessment; oxygen desaturation predicts poor outcomes

Echocardiography: [43,58]

• Annual screening for all SSc patients
• Assess:
  • "RVSP estimation (TR velocity): RVSP > 40 mmHg warrants further PAH evaluation"
  • RV size and function
  • LV systolic and diastolic function
  • Pericardial effusion
• Limitations: Cannot definitively diagnose PAH (requires RHC)

Right Heart Catheterization (RHC): [44]

• Indications:
  • RVSP > 40 mmHg on echo
  • Isolated DLCO less than 60% predicted
  • Unexplained dyspnea with clinical suspicion of PAH
• Diagnostic Criteria for PAH:
  • Mean PAP ≥20 mmHg (2022 ESC/ERS definition)
  • PCWP ≤15 mmHg (excludes pulmonary venous hypertension from LV disease)
  • PVR ≥3 Wood units
• Risk Stratification: Cardiac index, RA pressure, mixed venous oxygen saturation

Cardiovascular Assessment

Electrocardiogram (ECG): [50]

• Baseline and annually
• Findings: Conduction delays (AV block, RBBB, LBBB), arrhythmias (PVCs, VT), low voltage (pericardial effusion)

24-Hour Holter Monitor:

• If symptoms (palpitations, syncope, presyncope)
• Detect occult arrhythmias (ventricular ectopy, non-sustained VT)

Cardiac MRI: [51]

• Indications: Suspected myocardial involvement, abnormal echo, high troponin/BNP
• Findings:
  • "Late gadolinium enhancement (LGE): Patchy fibrosis (replacement or interstitial)"
  • Reduced LVEF or RVEF
  • Myocardial edema (T2-weighted imaging)
• Prognostic: Presence and extent of LGE predicts arrhythmias and mortality

Biomarkers:

• NT-proBNP / BNP: Elevated in PAH, LV dysfunction, RV dysfunction
• High-Sensitivity Troponin: Elevated in myocardial fibrosis/injury

Gastrointestinal Assessment

Barium Swallow / Esophageal Manometry: [59]

• Findings: Esophageal dysmotility (hypomotility or aperistalsis), dilated esophagus, reduced LES tone
• Manometry: Quantifies peristaltic amplitude and LES pressure

Upper Endoscopy (OGD):

• Evaluate for: Esophagitis, Barrett's esophagus (from chronic GERD), GAVE (watermelon stomach)

Gastric Emptying Study:

• If symptoms of gastroparesis (early satiety, nausea, vomiting)

Small Bowel Breath Testing:

• Hydrogen-methane breath test for bacterial overgrowth

Contrast CT Abdomen/Pelvis:

• If suspected pseudo-obstruction, pneumatosis intestinalis

Nailfold Capillaroscopy

Technique: [60]

• Non-invasive visualization of nailfold capillaries using dermatoscope or videocapillaroscopy
• Examines 4th and 5th fingers of both hands

SSc-Specific Patterns:

• Early: Dilated capillaries, few hemorrhages
• Active: Frequent hemorrhages, moderate capillary loss, moderate disorganization
• Late: Severe capillary loss, extensive avascularity, neoangiogenesis (bushy capillaries)

Utility:

• Distinguish SSc-spectrum Raynaud's from primary Raynaud's
• Predict progression from undifferentiated connective tissue disease (UCTD) to SSc
• Risk stratification for digital ulcers

Skin Biopsy

• Rarely needed for diagnosis (clinical + serology usually sufficient)
• Indications: Atypical presentation, exclude differential diagnoses (morphea, eosinophilic fasciitis)
• Findings: Thickened dermis, dense collagen bundles, reduced appendages, perivascular inflammation (early)

Other Investigations

Modified Rodnan Skin Score (mRSS): [32]

• Clinical assessment (not laboratory/imaging)
• Semi-quantitative scoring of skin thickness (0-3) in 17 body areas
• Total score 0-51
• Used to track disease progression and treatment response

Bone Densitometry (DEXA):

• Assess for osteoporosis (risk from corticosteroids, reduced mobility, malabsorption)

Malignancy Screening: [55]

• Age-appropriate cancer screening for all
• Enhanced screening if anti-RNA Polymerase III positive (within 2 years of SSc diagnosis):
  • Mammography, colonoscopy, skin examination, CT chest
  • Consider PET-CT if high suspicion

---

8. Diagnosis and Classification

Diagnostic Approach

SSc is a clinical diagnosis supported by serological and imaging findings. No single test is diagnostic.

Typical Presentation:

1. Raynaud's phenomenon (especially with digital ulcers, pitting scars, or abnormal capillaroscopy)
2. Skin thickening (sclerodactyly or more extensive)
3. SSc-specific autoantibody (ACA, anti-Scl-70, anti-RNA Pol III)
4. Internal organ involvement (ILD, PAH, GERD, etc.)

2013 ACR/EULAR Classification Criteria

The 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis replaced the 1980 ACR criteria, improving sensitivity for early and limited disease. [61]

Scoring System (Total score ≥9 definite SSc):

Interpretation:

• Score ≥9: Definite SSc
• Score less than 9: Does not meet classification criteria (but does not exclude SSc)
• These are classification criteria (for research), not diagnostic criteria, but widely used clinically

Example:

• Patient with sclerodactyly (4 points) + Raynaud's (3 points) + anti-Scl-70 (3 points) = 10 points → Definite SSc

Very Early Diagnosis of SSc (VEDOSS)

VEDOSS criteria identify patients at high risk for developing definite SSc: [62]

• Raynaud's phenomenon AND
• SSc-specific autoantibodies (ACA, anti-Scl-70, anti-RNA Pol III) AND/OR abnormal nailfold capillaroscopy
• But do NOT yet meet 2013 ACR/EULAR criteria

Significance: High proportion (> 60%) progress to definite SSc within 5 years; candidates for early monitoring and intervention trials.

---

9. Management

SSc management is organ-based and multidisciplinary, as no single disease-modifying therapy addresses all manifestations. Early detection and treatment of organ involvement improves outcomes. [63,64]

General Principles

1. Early Diagnosis and Risk Stratification: Identify organ involvement and high-risk features
2. Regular Monitoring: Annual (or more frequent) screening for ILD, PAH, renal crisis
3. Organ-Specific Therapy: Tailored treatment based on manifestations
4. Multidisciplinary Care: Rheumatology, pulmonology, cardiology, nephrology, gastroenterology, dermatology
5. Patient Education: Disease course, self-monitoring (BP for renal crisis), trigger avoidance (cold, smoking)
6. Supportive Care: Physiotherapy, occupational therapy, psychological support

Management by Organ System

Raynaud's Phenomenon and Digital Ulcers

Non-Pharmacological: [65]

• Smoking cessation (critical; smoking worsens vasospasm and ulcers)
• Keep warm (whole body, not just extremities; layered clothing, heated gloves)
• Avoid triggers: Cold, emotional stress, vibration, vasoconstrictive drugs (decongestants, beta-blockers)
• Protect digits from trauma

Pharmacological for Raynaud's:

Digital Ulcer Management: [30,70]

• Wound Care: Moist wound dressings, avoid trauma, infection surveillance (swab if signs of infection)
• Analgesia: Often requires opioids for severe ischemic pain
• Optimize Vasodilators: Ensure on adequate doses of CCB, PDE5i
• IV Iloprost: For active ulcers or critical ischemia
• Bosentan: For prevention of recurrent ulcers (RAPIDS-1, RAPIDS-2 trials showed 30-50% reduction in new ulcers) [69]
• Surgical: Rarely, sympathectomy or digital amputation for unreconstructable ischemia

Critical Digital Ischemia:

• Medical emergency; hospitalize
• IV prostacyclin (iloprost or epoprostenol)
• Antiplatelet agents (aspirin)
• Consider anticoagulation
• Pain management
• Vascular surgery consultation (rarely, revascularization or amputation)

Skin Disease

No consistently effective disease-modifying therapy for skin fibrosis. Treatment focuses on early, rapidly progressive diffuse disease. [71]

Pharmacological:

Non-Pharmacological:

• Physiotherapy: Joint range of motion exercises, prevent contractures
• Occupational Therapy: Assistive devices, hand exercises
• Skin Care: Emollients, avoid trauma
• UV Phototherapy: Limited evidence; possibly helpful for early inflammatory skin

Autologous Stem Cell Transplantation (ASCT): [75,78]

• Indication: Severe, rapidly progressive dcSSc (increasing mRSS, early disease less than 5 years), age less than 65, no severe organ failure
• ASTIS Trial: Compared ASCT vs IV cyclophosphamide
  • ASCT showed better long-term survival (HR 0.34 at 10 years)
  • Higher early mortality (treatment-related mortality ~10% in trial; lower in modern protocols)
• Performed at specialist centers with experience in HSCT for autoimmune disease
• Selection criteria critical; multidisciplinary assessment

Interstitial Lung Disease (ILD)

ILD is the leading cause of death in SSc. Early detection and treatment are critical. [24,38]

Indications for Treatment: [79]

• Symptomatic ILD (dyspnea, cough)
• Progressive ILD: Declining FVC (> 10% decline over 12 months, or 5-10% with symptoms/imaging progression)
• Extensive ILD on HRCT (> 20% lung involvement)
• High-risk features: dcSSc, anti-Scl-70, African ancestry, male sex

First-Line Immunosuppression:

Antifibrotic Therapy:

Combination Therapy:

• MMF + Nintedanib: Increasingly used; SENSCIS trial allowed background MMF
• Rationale: Immunosuppression (MMF) + antifibrotic (nintedanib) target different pathways

Other Therapies (Limited Evidence):

• Rituximab: B-cell depletion; case series show possible benefit [80]
• Tocilizumab: IL-6 inhibition; focuSSced trial showed preserved FVC [77]
• Pirfenidone: Antifibrotic; limited data in SSc-ILD (more evidence in IPF)

Monitoring:

• PFTs every 3-6 months (FVC, DLCO)
• HRCT every 12-24 months or if clinical/PFT decline
• 6-Minute Walk Test
• Treatment response: Stabilization of FVC is success (disease is progressive without treatment)

Lung Transplantation: [81]

• Indication: Progressive ILD despite maximal medical therapy, FVC less than 50%, severe hypoxemia, poor functional status
• Outcomes: SSc patients have similar post-transplant survival to IPF patients (~50-60% at 5 years)
• Challenges: Esophageal dysmotility increases aspiration risk; need careful perioperative management

Pulmonary Arterial Hypertension (PAH)

SSc-PAH has worse prognosis than idiopathic PAH and requires aggressive, early treatment. [42,82]

Risk Stratification: [83]

• Low Risk: WHO FC I-II, 6MWT > 440 m, RA pressure less than 8 mmHg, cardiac index > 2.5 L/min/m²
• Intermediate Risk: Intermediate values
• High Risk: WHO FC IV, 6MWT less than 165 m, RA pressure > 14 mmHg, cardiac index less than 2.0 L/min/m²

Treatment Goals: [44]

• Achieve/maintain low-risk status
• Targets: WHO FC I-II, 6MWT > 440 m, NT-proBNP less than 300 ng/L

Pharmacological Therapy:

Initial Strategy Based on Risk: [84]

PAH-Specific Medications:

Initial Combination Therapy: [85]

• AMBITION trial: Ambrisentan + tadalafil superior to monotherapy (reduced clinical failure events by 50%)
• Upfront dual therapy (ERA + PDE5i) is now standard for most patients

Sequential Add-On Therapy:

• If inadequate response to dual therapy → add prostacyclin pathway agent (selexipag or parenteral prostacyclin)

Supportive Therapy:

• Diuretics: For fluid overload
• Oxygen: If hypoxemic
• Anticoagulation: Controversial in SSc-PAH (used in iPAH); consider if low bleeding risk
• Digoxin: For rate control if AF

Monitoring:

• Every 3-6 months: WHO FC, 6MWT, NT-proBNP, echocardiography
• Risk re-assessment: Adjust therapy if not achieving/maintaining low-risk status
• RHC: At baseline, after major therapy escalation, if clinical deterioration

Lung Transplantation: [81]

• Consider if refractory PAH despite maximal medical therapy
• SSc-PAH patients are eligible for transplant

Scleroderma Renal Crisis (SRC)

Covered in detail in Section 5 (Renal Manifestations).

Key Points:

• Medical Emergency
• Immediate ACE Inhibitor (captopril 6.25-12.5 mg q6-8h, titrate rapidly)
• Continue ACEi even if creatinine rises
• Avoid corticosteroids (precipitant)
• Dialysis often required; renal function may recover over months

Prevention: [48]

• Avoid high-dose corticosteroids (> 15 mg/day prednisone) in dcSSc
• Home BP monitoring in high-risk patients (dcSSc, anti-RNA Pol III, rapid skin progression)
• Rapid treatment of new-onset hypertension

Gastrointestinal Disease

Gastroesophageal Reflux (GERD): [86]

• High-dose PPI: Omeprazole 40 mg daily, or equivalent (may need BD dosing)
• Prokinetics: Metoclopramide 10 mg TDS, Domperidone 10 mg TDS (limited efficacy; cardiac side effects)
• Lifestyle: Elevate head of bed, small frequent meals, avoid late-night eating, avoid trigger foods
• Monitoring: Endoscopy for Barrett's esophagus surveillance (every 3-5 years if present)

Esophageal Strictures:

• Endoscopic dilation

Gastroparesis: [87]

• Prokinetics: Metoclopramide, domperidone
• Dietary: Small, frequent, low-fat meals
• Refractory cases: Gastric electrical stimulation (investigational)

Gastric Antral Vascular Ectasia (GAVE):

• Argon Plasma Coagulation (APC): Endoscopic ablation; may require multiple sessions [35]
• Iron supplementation: For anemia
• Transfusions: If severe anemia

Small Intestinal Bacterial Overgrowth (SIBO): [36]

• Rotating Antibiotics: Rifaximin 550 mg BD × 14 days; Metronidazole 400 mg TDS × 14 days; Ciprofloxacin 500 mg BD × 14 days (cycle different antibiotics to prevent resistance)
• Probiotics: Limited evidence
• Nutritional Support: If malabsorption

Pseudo-obstruction:

• Conservative: NPO, NG decompression, IV fluids, octreotide
• Surgery: Rarely needed; high morbidity

Fecal Incontinence:

• Anal manometry assessment
• Biofeedback therapy, bulking agents
• Rarely, colostomy for severe cases

Cardiac Disease

Heart Failure: [50]

• Guideline-based HF therapy: ACEi/ARB, beta-blockers, MRAs, diuretics, SGLT2i
• Device Therapy: ICD if high-risk arrhythmias, CRT if indicated

Arrhythmias:

• Conduction Disease: Pacemaker for symptomatic bradycardia, high-grade AV block
• Ventricular Arrhythmias: ICD if sustained VT/VF, high-risk features (extensive LGE on MRI, LVEF less than 35%)

Pericardial Effusion:

• Small, asymptomatic: Monitor
• Moderate-large, symptomatic: NSAIDs, colchicine, corticosteroids (low-dose)
• Tamponade: Pericardiocentesis

Musculoskeletal

Arthritis/Arthralgia:

• NSAIDs (use cautiously; renal/GI risks)
• Low-dose corticosteroids (less than 10 mg/day) if needed (avoid high doses in dcSSc)
• Methotrexate if inflammatory arthritis

Myositis (overlap syndrome):

• Corticosteroids (prednisolone 0.5-1 mg/kg)
• Steroid-sparing agents: Methotrexate, azathioprine, mycophenolate

Joint Contractures:

• Physiotherapy, occupational therapy
• Splints to maintain range of motion
• Rarely, surgical release

Other Manifestations

Sicca Syndrome:

• Artificial tears, saliva substitutes
• Pilocarpine or cevimeline if severe
• Dental hygiene

Sexual Dysfunction:

• Erectile Dysfunction: PDE5 inhibitors (sildenafil, tadalafil) - dual benefit for Raynaud's
• Vaginal Dryness: Lubricants, topical estrogen

Calcinosis:

• No proven effective therapy
• Surgical excision if symptomatic
• Investigational: Diltiazem, minocycline, warfarin, bisphosphonates (limited evidence)

Malignancy Surveillance: [55]

• Age-appropriate screening
• Enhanced screening if anti-RNA Pol III positive

Experimental and Emerging Therapies

Targeted Therapies Under Investigation: [88,89]

Novel Targets:

• TGF-β pathway inhibitors: Multiple agents in preclinical/early clinical development
• Tyrosine kinase inhibitors: Target pro-fibrotic signaling
• Antifibrotic agents: Beyond nintedanib

---

10. Monitoring and Follow-Up

SSc requires lifelong monitoring due to risk of progressive organ involvement and late complications. [64,90]

Baseline Assessment (At Diagnosis)

• Clinical: Full history, examination (skin score, BP, cardiac/pulmonary exam)
• Serology: ANA, SSc-specific antibodies, CBC, renal function, LFTs, CK, TSH, urinalysis
• Pulmonary: PFTs (FVC, DLCO), HRCT chest, echocardiography
• Cardiac: ECG, echocardiography, consider NT-proBNP, troponin
• GI: Upper endoscopy if GERD symptoms
• Nailfold Capillaroscopy: If available
• Skin: Modified Rodnan Skin Score

Annual Monitoring (Minimum)

High-Risk Monitoring

Scleroderma Renal Crisis Risk (dcSSc, anti-RNA Pol III, rapid skin progression, new cardiac event):

• Home BP monitoring: Daily or alternate days
• Renal function: Monthly creatinine
• Urgent evaluation if: New-onset hypertension, rising creatinine, headache, visual changes

Progressive ILD Risk (dcSSc, anti-Scl-70, baseline ILD, African ancestry):

• PFTs: Every 3-6 months
• HRCT: Repeat if symptoms or PFT decline
• Consider early treatment if progressive

PAH Risk (lcSSc, anti-centromere, isolated DLCO reduction, late disease):

• Annual screening: Echo + DLCO
• Low threshold for RHC if RVSP > 40 mmHg or DLCO less than 60%

---

11. Prognosis and Outcomes

Survival

Overall Survival: [91,92]

• 10-year survival: 70-80% overall
• Limited Cutaneous SSc: 10-year survival ~75-85%
• Diffuse Cutaneous SSc: 10-year survival ~55-70%

Survival has improved over past decades due to:

• Earlier diagnosis
• Organ-specific therapies (ACEi for SRC, PAH therapies, immunosuppression for ILD)
• Better supportive care

Causes of Death

Primary Causes: [4,93]

1. Pulmonary Complications (50-60% of SSc-related deaths):

   • Interstitial lung disease (ILD): Leading cause in dcSSc
   • Pulmonary arterial hypertension (PAH): Leading cause in lcSSc
   • Combined ILD-PAH

2. Cardiac Disease (15-20%):

   • Heart failure (from myocardial fibrosis or PAH)
   • Arrhythmias/sudden cardiac death
   • Myocardial infarction (rare)

3. Scleroderma Renal Crisis (5-10%):

   • Dramatically reduced since ACEi era (was leading cause pre-1980s)

4. Gastrointestinal (5%):

   • Malabsorption, pseudo-obstruction, GAVE bleeding

5. Infection (10%):

   • Pneumonia, sepsis (often related to immunosuppression)

6. Malignancy (5-10%):

   • Slightly increased cancer risk

Prognostic Factors

Poor Prognosis Indicators: [94]

Better Prognosis Indicators:

• Limited cutaneous subtype
• Anti-centromere antibody (lcSSc; but still risk of late PAH)
• Isolated skin disease without organ involvement
• Early diagnosis and treatment

Disease Course

Limited Cutaneous SSc:

• Indolent: Slow progression over decades
• Raynaud's first: Often 10-20 years before other features
• Late complications: PAH typically develops > 10-15 years after diagnosis
• Stable skin: Minimal skin progression after initial phase

Diffuse Cutaneous SSc:

• Rapid onset: Skin changes within 1 year of Raynaud's
• Peak skin involvement: 3-5 years, then may stabilize or improve ("burn-out")
• Early organ complications: ILD, renal crisis occur in first 3-5 years
• Bimodal mortality: Early peak (first 3-5 years from organ complications) and late peak (long-term organ damage)

Quality of Life

Significant Impact on QoL: [95]

• Fatigue: Profound, pervasive, often most disabling symptom
• Pain: Digital ulcers, arthralgia, GERD
• Functional Limitation: Hand contractures, reduced oral aperture, dysphagia, dyspnea
• Cosmetic: Facial changes, skin tightness, calcinosis
• Psychological: Anxiety, depression common
• Sexual dysfunction: Affects intimacy

Interventions to Improve QoL:

• Multidisciplinary support (physiotherapy, occupational therapy, psychology)
• Patient education and support groups
• Symptom management
• Addressing cosmetic concerns (e.g., telangiectasia laser therapy)

---

12. Complications

Major Organ Complications

Detailed in Section 5 (Clinical Presentation). Summary:

• Interstitial Lung Disease: Progressive fibrosis, respiratory failure
• Pulmonary Arterial Hypertension: Right ventricular failure
• Scleroderma Renal Crisis: AKI, malignant hypertension, MAHA, dialysis-dependence
• Cardiac Fibrosis: Heart failure, arrhythmias, sudden death
• Gastrointestinal: Malabsorption, pseudo-obstruction, GAVE bleeding
• Digital Ulcers: Chronic pain, infection, gangrene

Treatment-Related Complications

Immunosuppression:

• Infection risk: Opportunistic infections (PCP, TB reactivation), bacterial/viral infections
• Bone marrow suppression: Cytopenias
• Hepatotoxicity: Monitor LFTs (methotrexate, azathioprine)
• Teratogenicity: Methotrexate, mycophenolate, cyclophosphamide

Corticosteroids:

• Scleroderma renal crisis: Major precipitant at high doses (> 15 mg/day)
• Osteoporosis, diabetes, infection, weight gain, adrenal suppression

PAH Medications:

• Hepatotoxicity: ERAs (bosentan requires monthly LFTs)
• Peripheral edema: ERAs, CCBs
• Headache, flushing, GI upset: Prostacyclins
• Anemia: ERAs

Nintedanib:

• Diarrhea: Very common; may require dose reduction
• Nausea, vomiting, abdominal pain
• Hepatotoxicity: Monitor LFTs

Autologous Stem Cell Transplant:

• Treatment-related mortality: 5-10% (higher in early trials; improving)
• Infection: During neutropenic phase
• Organ toxicity: Cardiac, pulmonary, renal

---

13. Prevention

Primary Prevention

No proven interventions to prevent SSc in at-risk individuals.

Potential Modifiable Risk Factors:

• Avoid occupational exposures: Silica dust, organic solvents (if occupationally exposed, use protective equipment, surveillance)
• Smoking cessation: May reduce disease severity (not proven to prevent disease)

Secondary Prevention (Prevent Progression from Early to Definite Disease)

Very Early Diagnosis of SSc (VEDOSS): [62]

• Patients with Raynaud's + SSc-specific antibodies/abnormal capillaroscopy
• Close monitoring for progression to definite SSc
• Clinical trials: Investigating early immunosuppression to prevent progression

Tertiary Prevention (Prevent Organ Complications)

Prevent Scleroderma Renal Crisis: [48]

• Avoid high-dose corticosteroids in dcSSc (> 15 mg/day)
• Home BP monitoring in high-risk patients
• Early ACEi for new-onset hypertension

Prevent ILD Progression: [79]

• Early immunosuppression (MMF, CYC) for progressive ILD
• Smoking cessation
• Avoid environmental lung irritants

Prevent PAH: [43]

• Annual screening (echo, DLCO)
• Early RHC and treatment if PAH detected
• No proven preventive therapies

Prevent Digital Ulcers: [70]

• Smoking cessation (critical)
• Optimize vasodilators: CCBs, PDE5i
• Bosentan: Reduces new ulcer occurrence by 30-50% (RAPIDS trials) [69]
• Avoid trauma: Protective gloves, careful nail care
• Keep warm

Prevent Gastrointestinal Complications:

• High-dose PPI: Prevent esophagitis, strictures, Barrett's esophagus
• Endoscopy surveillance: For Barrett's esophagus (every 3-5 years if present)
• SIBO prophylaxis: Rotating antibiotics if recurrent

Prevent Infections:

• Vaccinations: Influenza (annual), pneumococcal (PPSV23, PCV13), COVID-19, herpes zoster (if age-appropriate and not on high-dose immunosuppression)
• PCP prophylaxis: If on high-dose or combination immunosuppression (co-trimoxazole 480 mg daily or 960 mg thrice weekly)

Prevent Osteoporosis:

• DEXA scan: Baseline and repeat if on corticosteroids
• Calcium and vitamin D supplementation
• Bisphosphonates if osteoporotic or on long-term steroids

---

14. Patient and Layperson Explanation

What is Systemic Sclerosis?

Systemic Sclerosis, also called Scleroderma, is a rare condition where your body's immune system mistakenly attacks your own tissues (an "autoimmune" disease). This causes two main problems:

1. Thickening and hardening of the skin ("sclero" = hard, "derma" = skin)
2. Damage to blood vessels and internal organs like the lungs, heart, kidneys, and digestive system

The disease varies greatly between people. Some have mild disease affecting mainly the skin, while others have more severe disease affecting internal organs.

What causes it?

We don't know exactly what triggers Systemic Sclerosis. It's thought to be a combination of:

• Genetics: Some people are born with genes that make them more susceptible
• Environmental triggers: Exposure to certain chemicals (like silica dust or solvents) or infections may trigger the disease in susceptible people
• Hormones: The disease is more common in women, suggesting hormones may play a role

It is not contagious – you cannot catch it from someone else.

What are the symptoms?

Common symptoms include:

• Cold fingers (Raynaud's phenomenon): Your fingers turn white, then blue, then red when exposed to cold or stress. This happens because the blood vessels in your fingers temporarily narrow. Nearly everyone with Systemic Sclerosis has this.

• Tight, thickened skin: The skin on your hands and fingers becomes tight, shiny, and hard. In more severe cases, this can spread to your arms, face, and body.

• Heartburn and difficulty swallowing: The esophagus (food pipe) can become stiff and not work properly, causing acid reflux.

• Shortness of breath: Some people develop scarring in the lungs (called "interstitial lung disease") or high blood pressure in the lung arteries (called "pulmonary hypertension"), which can make you breathless.

• Fatigue: Feeling extremely tired is very common and can be one of the most troublesome symptoms.

Is it dangerous?

Systemic Sclerosis can be serious, especially if it affects internal organs. The main concerns are:

• Lung problems: Scarring of the lungs or high pressure in the lung arteries can make it hard to breathe and are the most common serious complications.

• Kidney crisis: A sudden spike in blood pressure that can damage your kidneys. This is rare but requires immediate treatment.

• Heart problems: The heart muscle can become stiff and scarred, leading to heart rhythm problems or heart failure in some cases.

The good news: With regular monitoring and treatment, many of these complications can be detected early and managed effectively. Many people with Systemic Sclerosis live full, active lives.

How is it treated?

There is no cure for Systemic Sclerosis yet, but we can manage symptoms and prevent complications:

For Raynaud's (cold fingers):

• Keep your whole body warm (not just your hands)
• Stop smoking (very important!)
• Medications to open up blood vessels (like nifedipine or amlodipine)

For tight skin:

• Moisturizers and skin care
• Physiotherapy and exercises to keep your joints flexible
• In severe cases, medications to slow skin thickening

For heartburn:

• Acid-suppressing medications (like omeprazole)
• Eat smaller meals, avoid eating late at night, elevate the head of your bed

For lung problems:

• Medications to prevent scarring from getting worse (like mycophenolate or nintedanib)
• Medications to reduce pressure in the lung arteries if needed
• Oxygen therapy if you're breathless

For kidney crisis:

• Medications called ACE inhibitors (like captopril) can be life-saving
• Monitor your blood pressure at home if you're at high risk

Regular check-ups are crucial: You'll need regular tests (breathing tests, heart scans, blood tests) to check how your organs are doing and catch any problems early.

What can I do to help myself?

• Stop smoking: Smoking makes Raynaud's and lung disease much worse
• Stay warm: Dress in layers, use heated gloves, avoid air conditioning
• Protect your skin: Use moisturizers, protect your hands from injury
• Eat well: Small, frequent meals if you have swallowing or digestive problems
• Stay active: Gentle exercise and stretching help keep joints flexible
• Monitor your blood pressure: If you're at risk for kidney problems, check your BP regularly at home
• Attend appointments: Regular monitoring helps catch problems early
• Seek support: Connect with patient support groups (like Scleroderma & Raynaud's UK or similar organizations in your country)

Will I pass this on to my children?

Systemic Sclerosis itself is not directly inherited, but there is a slightly higher risk in family members (about 1-2% risk in relatives compared to the general population risk of much less than 1%). The vast majority of people with Systemic Sclerosis do not have affected family members.

What is the outlook?

The outlook varies greatly depending on which type of Systemic Sclerosis you have and whether your internal organs are affected:

• Limited disease (affecting skin mainly on hands, feet, and face): Generally slower progression with better long-term outlook
• Diffuse disease (affecting skin on the body as well): Can be more aggressive, especially in the first few years, but often stabilizes

With modern treatments and careful monitoring, most people with Systemic Sclerosis can expect to live many years with a good quality of life. Early diagnosis and treatment of organ involvement has dramatically improved outcomes.

---

15. Key Guidelines and Evidence

International Guidelines

Landmark Clinical Trials

1. Scleroderma Renal Crisis - ACE Inhibitors [99]

• Study: Observational, before-after comparison (pre- vs post-ACEi era)
• Finding: ACEi (captopril) improved 1-year survival from less than 10% to > 70%
• Impact: ACEi became standard of care for SRC

2. Scleroderma Lung Study I (SLS I) [74]

• Design: RCT, Cyclophosphamide vs Placebo (n=158)
• Finding: CYC improved FVC by modest ~2-3% at 12 months vs placebo
• Limitation: Benefit modest and declined after stopping CYC
• Impact: Established immunosuppression benefits SSc-ILD

3. Scleroderma Lung Study II (SLS II) [73]

• Design: RCT, Mycophenolate Mofetil (24 months) vs Cyclophosphamide (12 months) (n=142)
• Finding: MMF non-inferior to CYC for FVC improvement; MMF had better tolerability and sustained benefit
• Impact: MMF became first-line therapy for SSc-ILD

4. SENSCIS Trial [76]

• Design: RCT, Nintedanib vs Placebo (n=576)
• Finding: Nintedanib reduced FVC decline by ~50% (41% reduction in annual rate of decline)
• Adverse Events: Diarrhea common (76% vs 32%)
• Impact: Nintedanib approved for SSc-ILD; can combine with MMF

5. focuSSced Trial [77]

• Design: RCT, Tocilizumab (IL-6 inhibitor) vs Placebo (n=210)
• Finding: Preserved FVC vs placebo; possible skin benefit; no PAH benefit
• Impact: Tocilizumab emerging as option for SSc-ILD; further studies ongoing

6. ASTIS Trial [75]

• Design: RCT, Autologous Stem Cell Transplant vs IV Cyclophosphamide (n=156)
• Finding: ASCT improved long-term survival (HR 0.34 at 10 years) but higher early mortality (treatment-related mortality ~10%)
• Impact: ASCT option for selected patients with severe, early, progressive dcSSc

7. RAPIDS-1 and RAPIDS-2 Trials [69]

• Design: RCTs, Bosentan vs Placebo for digital ulcer prevention
• Finding: Bosentan reduced new digital ulcers by ~30-50%
• Impact: Bosentan approved for digital ulcer prevention (though not universally reimbursed)

8. AMBITION Trial (PAH) [85]

• Design: RCT, Ambrisentan + Tadalafil vs monotherapy (n=500, ~40% SSc-PAH)
• Finding: Combination therapy reduced clinical failure events by 50%
• Impact: Initial combination therapy became standard for PAH (including SSc-PAH)

---

16. Examination Focus (MRCP/Postgraduate)

Common Exam Scenarios

Station: Examine this patient's hands

Findings:

• Sclerodactyly (tight, shiny skin on fingers)
• Flexion contractures
• Digital pitting scars or active ulcers
• Calcinosis (palpable subcutaneous nodules)
• Telangiectasias (face, hands)
• Nailfold capillary changes (if examined)

Expected Discussion:

• "This patient has Systemic Sclerosis with sclerodactyly, digital pitting scars, and telangiectasias."
• Classify: Limited vs diffuse (ask about skin involvement on arms, chest)
• Ask about Raynaud's phenomenon
• Screen for organ involvement: Dyspnea (ILD, PAH), GERD, BP (renal)
• Antibody discussion: ACA (limited), Scl-70 (diffuse + ILD), RNA Pol III (renal crisis)

Station: Breathless patient with Systemic Sclerosis

Approach:

1. History: Onset, progression, exertional vs rest, orthopnea (PAH/LV failure)
2. Differentiate:
   • ILD: Dry cough, crackles, restrictive PFTs, ground-glass on HRCT
   • PAH: Exertional dyspnea, loud P2, elevated RVSP on echo
   • Cardiac: LV failure from myocardial fibrosis
   • Aspiration: From esophageal dysmotility
3. Investigations: PFTs (FVC, DLCO), HRCT, Echo, NT-proBNP, RHC if PAH suspected
4. Management: Depends on cause (MMF/nintedanib for ILD, PAH-specific therapy for PAH)

High-Yield Viva Questions and Model Answers

Q1: A patient with diffuse cutaneous SSc presents with BP 190/110 mmHg and creatinine 380 μmol/L (baseline 90). What is the diagnosis and immediate management?

Model Answer:

• Diagnosis: Scleroderma Renal Crisis (SRC)
• Pathophysiology: Thrombotic microangiopathy of renal arterioles triggered by RAAS activation
• Immediate Management:
  1. ACE Inhibitor: Captopril 6.25-12.5 mg PO q6-8h; titrate rapidly to max dose or BP less than 120/80 mmHg
  2. Continue ACEi even if creatinine rises (renal function may recover over months)
  3. Check for MAHA: Blood film (schistocytes), LDH, haptoglobin, platelets
  4. Add further antihypertensives if needed (CCB, ARB), avoid beta-blockers
  5. Prepare for dialysis (may be required in 50-80%; continue ACEi during dialysis)
  6. AVOID corticosteroids (precipitant; taper if patient is on them)
• Prognosis: 70-80% 1-year survival with ACEi (vs less than 10% pre-ACEi era); 50% recover enough to stop dialysis

Q2: What is the first-line treatment for progressive SSc-ILD?

Model Answer:

• First-line: Mycophenolate Mofetil (MMF) 1-1.5 g BD (target 3 g/day)
• Evidence: SLS II trial showed MMF non-inferior to cyclophosphamide with better tolerability and sustained benefit
• Alternative: Cyclophosphamide (IV 500-750 mg/m² monthly or oral 1-2 mg/kg/day) if MMF contraindicated or insufficient
• Antifibrotic: Nintedanib 150 mg BD (SENSCIS trial: reduced FVC decline by ~50%); can combine with MMF
• Monitoring: PFTs every 3-6 months; goal is stabilization of FVC (disease is progressive without treatment)

Q3: How do you screen for and diagnose PAH in SSc?

Model Answer:

• Screening (annual for all SSc patients):
  • "Echocardiography: Estimate RVSP (TR velocity); RVSP > 40 mmHg warrants further evaluation"
  • "DLCO: Isolated reduction (less than 60% with preserved FVC) suggests PAH"
  • "NT-proBNP: Elevated if PAH present"
  • "6-Minute Walk Test: Reduced distance, oxygen desaturation"
• Diagnosis (definitive):
  • "Right Heart Catheterization (gold standard):"
    • Mean PAP ≥20 mmHg (2022 definition)
    • PCWP ≤15 mmHg (excludes left heart disease)
    • PVR ≥3 Wood units
• Exclude: ILD-associated PH (review HRCT, PFTs), CTEPH (V/Q scan, CT pulmonary angiography), left heart disease (echo, invasive hemodynamics)

Q4: What antibodies are associated with Systemic Sclerosis, and what are their clinical associations?

Model Answer:

• Antibodies are mutually exclusive in most patients

• 95% of SSc patients are ANA-positive

Q5: Why should high-dose corticosteroids be avoided in diffuse cutaneous SSc?

Model Answer:

• High-dose corticosteroids (> 15 mg/day prednisone) are a major precipitant of Scleroderma Renal Crisis
• Mechanism: Unclear; possibly causes renal vasoconstriction or RAAS activation
• Evidence: Observational studies show increased SRC risk with recent high-dose steroid use
• Clinical Implications:
  • Avoid high-dose steroids in dcSSc if possible
  • If steroids needed (e.g., myositis overlap), use lowest effective dose (less than 10 mg/day)
  • In SRC, taper steroids if patient is on them
• Note: Steroids are not effective for skin fibrosis in SSc (unlike other inflammatory diseases)

Q6: What is the CREST syndrome?

Model Answer:

• CREST is a mnemonic for features of limited cutaneous Systemic Sclerosis:
  • Calcinosis cutis
  • Raynaud's phenomenon
  • Esophageal dysmotility
  • Sclerodactyly
  • Telangiectasia
• Association: Anti-centromere antibody
• Prognosis: Better than diffuse SSc, but risk of late PAH (10-15%)
• Note: The term "CREST" is less commonly used now; "limited cutaneous SSc" is preferred

Q7: A patient with SSc has isolated reduction in DLCO (less than 60%) with normal FVC. What does this suggest and what is your next step?

Model Answer:

• Suggests: Pulmonary Arterial Hypertension (PAH)
• Mechanism: DLCO is sensitive to both ILD (alveolar pathology) and PAH (vascular pathology); isolated DLCO reduction (with normal FVC) suggests vascular rather than parenchymal lung disease
• Next Steps:
  1. Echocardiography: Estimate RVSP; if > 40 mmHg → high PAH suspicion
  2. NT-proBNP: Elevated if PAH present
  3. HRCT Chest: Exclude occult ILD
  4. Right Heart Catheterization: Definitive diagnosis if echo/clinical suspicion high
• Importance: Early detection of PAH improves outcomes; screening recommended annually in all SSc patients

Q8: Describe the typical HRCT findings in SSc-ILD.

Model Answer:

• Most Common Pattern: Nonspecific Interstitial Pneumonia (NSIP) (70-75%)
  • Ground-glass opacities (predominant feature)
  • Reticular changes (fine lines)
  • Subpleural sparing (distinguishes from UIP)
  • Lower lobe predominance
  • Temporally uniform (same age fibrosis throughout)
• Less Common Pattern: Usual Interstitial Pneumonia (UIP) (20-25%)
  • Honeycombing (cystic spaces with thick walls)
  • Traction bronchiectasis
  • Peripheral and basal predominance
  • No subpleural sparing
  • Worse prognosis than NSIP
• Quantification: Extent of disease (% lung involvement) predicts mortality; > 20% involvement is significant

---

17. Recent Advances and Future Directions

Recent Therapeutic Advances (2019-2026)

Nintedanib for SSc-ILD (Approved 2019): [76]

• Tyrosine kinase inhibitor targeting PDGFR, FGFR, VEGFR
• SENSCIS trial: Reduced FVC decline by ~50%
• Can combine with MMF
• Marks first antifibrotic approval for SSc

Tocilizumab (IL-6 Inhibition) (2020): [77]

• focuSSced trial: Preserved FVC vs placebo in SSc-ILD
• Possible skin benefit
• Further trials ongoing

Updated PAH Guidelines (ESC/ERS 2022): [44]

• New definition of PAH (mean PAP ≥20 mmHg, previously ≥25)
• Emphasis on initial combination therapy
• Risk stratification to guide treatment escalation

Improved ASCT Protocols: [100]

• Reduced treatment-related mortality (less than 5% in recent series vs ~10% in ASTIS)
• Better patient selection
• Remains option for severe, early, progressive dcSSc

Biomarkers Under Investigation

Prognostic Biomarkers: [101]

• Chemokines: CCL2, CXCL4 (predict ILD progression)
• KL-6 (Krebs von den Lungen-6): Elevated in ILD; correlates with disease activity
• SP-D (Surfactant Protein D): Lung epithelial injury marker
• MicroRNAs: miR-29, miR-21 (fibrosis regulation)
• Circulating Fibrocytes: Predict ILD progression

Diagnostic Biomarkers:

• Gene expression signatures to predict disease subset and outcomes
• Proteomic and metabolomic profiles

Emerging Therapies (Investigational)

Targeting Fibrosis Pathways: [88,102]

• Anti-TGF-β: Fresolimumab (anti-TGF-β antibody) - Phase II trials
• Tyrosine Kinase Inhibitors: Imatinib, nilotinib - mixed results
• JAK Inhibitors: Tofacitinib, baricitinib - small studies, ongoing trials
• Lysophosphatidic Acid (LPA) Pathway: LPAR1 antagonists

B-cell Targeting:

• Rituximab: Observational data suggest benefit for skin/ILD; RCTs ongoing [80]
• Rationale: B-cells produce pro-fibrotic cytokines and autoantibodies

Mesenchymal Stem Cells (MSCs):

• Immunomodulatory and potentially anti-fibrotic
• Small trials show safety; efficacy unclear

CAR-T Cell Therapy:

• Promising case reports in refractory autoimmune diseases
• Ultra-early research phase for SSc

Precision Medicine

Personalized Treatment Based on:

• Antibody profile: Tailor screening and treatment (e.g., aggressive BP monitoring if anti-RNA Pol III)
• Gene expression: Intrinsic subsets (inflammatory, fibroproliferative, limited, normal-like) may predict treatment response
• Biomarkers: Identify patients likely to progress (treat early) vs remain stable (avoid overtreatment)

Digital Health and Telemedicine

• Home spirometry: For frequent ILD monitoring
• Wearable devices: Activity monitoring, oxygen saturation
• Telemedicine: Improved access to multidisciplinary specialist care
• Patient-reported outcomes: Apps for symptom tracking (Raynaud's frequency, digital ulcers, GI symptoms)

---

18. References

Primary Sources (PubMed Indexed)

1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi:10.1016/S0140-6736(17)30933-9

2. Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002. doi:10.1038/nrdp.2015.2

3. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24(2):165-170. doi:10.1097/BOR.0b013e32834ff2e8

4. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-944. doi:10.1136/ard.2006.066068

5. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897-1905. doi:10.1136/annrheumdis-2017-211448

6. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6(2):112-116. doi:10.1038/nrrheum.2009.238

7. Ungprasert P, Wannarong T, Panichsillapakit T, et al. Outcome of patients with limited cutaneous systemic sclerosis and CREST syndrome: systematic review and meta-analysis. J Rheumatol. 2013;40(12):1956-1963. doi:10.3899/jrheum.130435

8. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000;43(2):444-451. doi:10.1002/1529-0131(200002)43:2less than 444::AID-ANR26> 3.0.CO;2-G

9. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37(1):42-53. doi:10.1111/j.1346-8138.2009.00762.x

10. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217-228. doi:10.1016/j.jaad.2010.05.045

11. Herrick AL, Ennis H, Bhushan M, et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken). 2010;62(2):213-218. doi:10.1002/acr.20070

12. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246-2255. doi:10.1002/art.11073

13. Radstake TR, Gorlova O, Rueda B, et al. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nat Genet. 2010;42(5):426-429. doi:10.1038/ng.565

14. Marie I, Gehanno JF, Bubenheim M, et al. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. Autoimmun Rev. 2014;13(2):151-156. doi:10.1016/j.autrev.2013.10.002

15. Sammaritano LR. Menopause in patients with autoimmune diseases. Autoimmun Rev. 2012;11(6-7):A430-A436. doi:10.1016/j.autrev.2011.11.006

16. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-567. doi:10.1172/JCI31139

17. Flavahan NA. A vascular mechanistic approach to understanding Raynaud phenomenon. Nat Rev Rheumatol. 2015;11(3):146-158. doi:10.1038/nrrheum.2014.195

18. Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002. doi:10.1038/nrdp.2015.2

---

Medical Disclaimer

MedVellum content is for educational purposes and clinical reference only. All clinical decisions must be individualized and should account for the specific patient's circumstances, comorbidities, and preferences. Always consult appropriate specialists for diagnosis and management of Systemic Sclerosis. This content does not replace clinical judgment or specialist consultation.

---

Topic Statistics:

• Total Sections: 18
• Word Count: ~14,500 words
• Citations: 18 primary sources (PubMed indexed)
• Tables: 15
• Target Examination: MRCP, FRACP, Rheumatology Specialty
• Difficulty: High (Postgraduate)
• Last Updated: 2026-01-07